These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
84 related items for PubMed ID: 3103772
41. [Renoprotective effect of monopril in patients with diabetes mellitus in the preclinical stage of diabetic nephropathy]. Lapchyns'ka II, Zhurylo TIe, Seliuk MM, Hromova AIe. Lik Sprava; 2002; (5-6):91-3. PubMed ID: 12442535 [Abstract] [Full Text] [Related]
42. [Prevention and protection in diabetic nephropathy]. Lidén MK. Lakartidningen; 2002; 110(21):1025-7. PubMed ID: 23805766 [No Abstract] [Full Text] [Related]
43. Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function. Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM. Br Med J (Clin Res Ed); 1984 Aug 11; 289(6441):347-8. PubMed ID: 6432091 [Abstract] [Full Text] [Related]
44. ACE-inhibition and renoprotection in early diabetic nephropathy. Response to enalapril acutely and in long-term combination with conventional antihypertensive treatment. Pedersen MM, Christensen CK, Hansen KW, Christiansen JS, Mogensen CE. Clin Invest Med; 1991 Dec 11; 14(6):642-51. PubMed ID: 1665407 [Abstract] [Full Text] [Related]
45. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Br Med J (Clin Res Ed); 1987 Jun 06; 294(6585):1443-7. PubMed ID: 3111583 [Abstract] [Full Text] [Related]
46. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. Casey RG, Joyce M, Roche-Nagle G, Chen G, Bouchier-Hayes D. J Surg Res; 2005 Feb 06; 123(2):176-81. PubMed ID: 15680375 [Abstract] [Full Text] [Related]
47. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Lacourcière Y, Bélanger A, Godin C, Hallé JP, Ross S, Wright N, Marion J. Kidney Int; 2000 Aug 06; 58(2):762-9. PubMed ID: 10916100 [Abstract] [Full Text] [Related]
48. [Increase glomerular filtration rate and urinary excretion of nitric oxide metabolites in diabetes. Modification with low captopril doses treatment]. Osorio-Bretón Mdel P. Rev Med Inst Mex Seguro Soc; 2008 Aug 06; 46(4):397-403. PubMed ID: 19213211 [Abstract] [Full Text] [Related]
49. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH. Kidney Int; 2001 Jul 06; 60(1):277-83. PubMed ID: 11422762 [Abstract] [Full Text] [Related]
50. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Joergensen C, Tarnow L, Goetze JP, Rossing P. Diabet Med; 2015 Mar 06; 32(3):374-81. PubMed ID: 25307511 [Abstract] [Full Text] [Related]
51. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR. Nephrol Dial Transplant; 2009 Jan 06; 24(1):73-84. PubMed ID: 18682491 [Abstract] [Full Text] [Related]
52. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Weidmann P, Schneider M, Böhlen L. Nephrol Dial Transplant; 1995 Oct 06; 10 Suppl 9():39-45. PubMed ID: 8643207 [No Abstract] [Full Text] [Related]
53. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. Pisoni R, Faraone R, Ruggenent P, Remuzzi G. J Nephrol; 2002 Oct 06; 15(4):428-30. PubMed ID: 12243375 [Abstract] [Full Text] [Related]
54. Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH. Kidney Int; 1999 Feb 06; 55(2):621-8. PubMed ID: 9987086 [Abstract] [Full Text] [Related]
55. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?]. Barnas U, Mayer G. Wien Klin Wochenschr; 1995 Feb 06; 107(1):10-4. PubMed ID: 7871784 [Abstract] [Full Text] [Related]
56. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy. Boels MG, Avramut MC, Koudijs A, Dane MJ, Lee DH, van der Vlag J, Koster AJ, van Zonneveld AJ, van Faassen E, Gröne HJ, van den Berg BM, Rabelink TJ. Diabetes; 2016 Aug 06; 65(8):2429-39. PubMed ID: 27207530 [Abstract] [Full Text] [Related]
57. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F. BMJ; 1996 Sep 07; 313(7057):591-4. PubMed ID: 8806248 [Abstract] [Full Text] [Related]
58. Hyperkalaemia induced by carbonic anhydrase inhibitor. Wakabayashi Y. Br J Ophthalmol; 1991 Mar 07; 75(3):176-7. PubMed ID: 2012787 [Abstract] [Full Text] [Related]
59. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. León Jiménez D, Cherney DZI, Bjornstad P, Castilla-Guerra L, Miramontes González JP. Am J Physiol Renal Physiol; 2018 Nov 01; 315(5):F1406-F1415. PubMed ID: 30066584 [Abstract] [Full Text] [Related]
60. Effects of acetazolamide on kidney function in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy. Skøtt P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH. Diabetologia; 1988 Nov 01; 31(11):806-10. PubMed ID: 3234635 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]